Literature DB >> 33382363

Immunostimulatory membrane proteins potentiate H. pylori-induced carcinogenesis by enabling CagA translocation.

Matthew G Varga1, Cecily R Wood2, Julia Butt3, Mackenzie E Ryan4, Wei-Cheng You5, Kaifeng Pan5, Tim Waterboer3, Meira Epplein6, Carrie L Shaffer2,4,7.   

Abstract

Infection with Helicobacter pylori is the single greatest risk factor for developing gastric adenocarcinoma. In prospective, population-based studies, seropositivity to the uncharacterized H. pylori proteins Hp0305 and Hp1564 was significantly associated with cancer risk in East Asia. However, the mechanism underlying this observation has not been elucidated. Here, we show that Hp0305 and Hp1564 act in concert with previously ascribed H. pylori virulence mechanisms to orchestrate cellular alterations that promote gastric carcinogenesis. In samples from 546 patients exhibiting premalignant gastric lesions, seropositivity to Hp0305 and Hp1564 was significantly associated with increased gastric atrophy across all stomach conditions. In vitro, depletion of Hp0305 and Hp1564 significantly reduced levels of gastric cell-associated bacteria and markedly impaired the ability of H. pylori to stimulate pro-inflammatory cytokine production. Remarkably, our studies revealed that Hp1564 is required for translocation of the oncoprotein CagA into gastric epithelial cells. Our data provide experimental insight into the molecular mechanisms governing novel H. pylori pathogenicity factors that are strongly associated with gastric disease and highlight the potential of Hp0305 and Hp1564 as robust molecular tools that can improve identification of individuals that are highly susceptible to gastric cancer. We demonstrate that Hp0305 and Hp1564 augment H. pylori-mediated inflammation and gastric cancer risk by promoting key bacteria-gastric cell interactions that facilitate delivery of oncogenic microbial cargo to target cells. Thus, therapeutically targeting microbial interactions driven by Hp0305/Hp1564 may enable focused H. pylori eradication strategies to prevent development of gastric malignancies in high-risk populations.

Entities:  

Keywords:  Helicobacter pylori ; CagA; bacterial pathogenesis; epidemiology; gastric cancer

Mesh:

Substances:

Year:  2021        PMID: 33382363      PMCID: PMC7781638          DOI: 10.1080/19490976.2020.1862613

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  33 in total

1.  Increased Outer Membrane Vesicle Formation in a Helicobacter pylori tolB Mutant.

Authors:  Lorinda Turner; Judyta Praszkier; Melanie L Hutton; David Steer; Georg Ramm; Maria Kaparakis-Liaskos; Richard L Ferrero
Journal:  Helicobacter       Date:  2015-02-09       Impact factor: 5.753

2.  Does Helicobacter pylori protect against asthma and allergy?

Authors:  Martin J Blaser; Yu Chen; Joan Reibman
Journal:  Gut       Date:  2008-01-14       Impact factor: 23.059

3.  Helicobacter pylori multiplex serology.

Authors:  Angelika Michel; Tim Waterboer; Manfred Kist; Michael Pawlita
Journal:  Helicobacter       Date:  2009-12       Impact factor: 5.753

4.  CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus.

Authors:  M F Vaezi; G W Falk; R M Peek; J J Vicari; J R Goldblum; G I Perez-Perez; T W Rice; M J Blaser; J E Richter
Journal:  Am J Gastroenterol       Date:  2000-09       Impact factor: 10.864

Review 5.  Helicobacter pylori and gastric cancer: factors that modulate disease risk.

Authors:  Lydia E Wroblewski; Richard M Peek; Keith T Wilson
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 6.  Helicobacter pylori and Extragastric Diseases.

Authors:  Andreas Kyburz; Anne Müller
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 7.  Helicobacter pylori: gastric cancer and beyond.

Authors:  D Brent Polk; Richard M Peek
Journal:  Nat Rev Cancer       Date:  2010-06       Impact factor: 60.716

8.  The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease.

Authors:  J J Vicari; R M Peek; G W Falk; J R Goldblum; K A Easley; J Schnell; G I Perez-Perez; S A Halter; T W Rice; M J Blaser; J E Richter
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteria-host cell interface.

Authors:  Carrie L Shaffer; Jennifer A Gaddy; John T Loh; Elizabeth M Johnson; Salisha Hill; Ewa E Hennig; Mark S McClain; W Hayes McDonald; Timothy L Cover
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

View more
  2 in total

1.  Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus.

Authors:  Anna K Miller; Gloria Tavera; Scott M Williams; Douglas R Morgan; Ricardo L Dominguez; M Constanza Camargo; Tim Waterboer; Keith T Wilson
Journal:  Oncogene       Date:  2021-08-10       Impact factor: 9.867

2.  A Predictive Model of Noncardia Gastric Adenocarcinoma Risk Using Antibody Response to Helicobacter pylori Proteins and Pepsinogen.

Authors:  John D Murphy; Andrew F Olshan; Feng-Chang Lin; Melissa A Troester; Hazel B Nichols; Julia Butt; You-Lin Qiao; Christian C Abnet; Manami Inoue; Shoichiro Tsugane; Meira Epplein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-04-01       Impact factor: 4.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.